Cytek Biosciences (CTKB) Operating Leases (2022 - 2026)

Cytek Biosciences' Operating Leases history runs 5 years deep, the most recent figure standing at $13.4 million for Q1 2026.

• Quarterly Operating Leases rose 80.46% year-over-year to $13.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.4 million (up 80.46% YoY) and the FY2025 annual result came in at $16.9 million, up 49.65% from the prior year.
• Operating Leases was $13.4 million for Q1 2026 at Cytek Biosciences, down from $16.9 million in the prior quarter.
• Across five years, Operating Leases topped out at $16.9 million in Q4 2025 and bottomed at $7.4 million in Q1 2025.
• A 5-year average of $12.4 million and a median of $12.3 million in 2022 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2025 — Operating Leases sank 32.14% — and 2026, when it soared 80.46%.
• Cytek Biosciences' Operating Leases stood at $15.2 million in 2022, then declined by 21.78% to $11.9 million in 2023, then fell by 5.16% to $11.3 million in 2024, then soared by 49.65% to $16.9 million in 2025, then slipped by 20.57% to $13.4 million in 2026.
• Business Quant data shows CTKB's Operating Leases at $13.4 million in Q1 2026, $16.9 million in Q4 2025, and $13.5 million in Q3 2025.